PPIs linked to chronic kidney disease

Patients on the drugs are 28 times more likely to have renal disease than those on H2 antagonists, research shows. 

Patients on proton pump inhibitors may need their renal function and electrolytes monitored while on therapy, US researchers say.

In their analysis, more than 42,500 adverse events reported to the US Food and Drug Administration by patients on PPI monotherapy were compared with more than 8300 reports from patients on histamine-2 receptor antagonists (H2RAs).

The frequency of adverse renal events was 5.6% for patients taking PPIs, but just 0.7% for patients taking H2RAs, according to the University of California researchers.

Patients on PPIs alone were 28 times more likely to report chronic kidney disease than those taking H2RAs, while the frequency of acute kidney injury reports was around four times higher, they write in Scientific Reports.

In their findings: 

  • Reports of end-stage renal disease were 35-fold higher among PPI users, while